{"prompt": "['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'The number and percent of subjects with treatment-emergent chemistry and hematology', 'abnormalities (low or high) as well as with CTCAE Grade >2 results after the first dose of', 'OLE study treatment will be summarized by laboratory parameter and by visit as well as', 'during the OLE study overall based on the most extreme subject values.', 'The number and percent of subjects with clinically significant urinalysis abnormalities will', 'be summarized by parameter (specific gravity, pH, protein, glucose, ketones, blood, and', 'leukocyte esterase) by visit as well as during the OLE study overall based on the most', 'extreme subject values.', 'Liver function parameters (AST, ALT, alkaline phosphatase, and total bilirubin) will be', 'summarized categorically using different levels of elevation thresholds (multiples of normal', \"range upper limit) as well as according to the criteria of Hy's Law.\", 'Lipid parameters (total cholesterol, HDL, LDL, and triglycerides) will be summarized by', 'means of descriptive statistics for the actual values and changes from Core Baseline and', 'OLE Baseline over time.', 'Clinically significant changes in vital signs will be identified and summarized for changes', 'from the Core Baseline values, OLE Baseline values, and last pre-OKZ values (see', 'Section 9.4.1).', 'Categorical ECG findings (normal; abnormal, not clinically significant; and abnormal,', 'clinically significant) will be summarized at each visit.', '9.4.7', 'Analysis of Efficacy Enppoints', 'Analysis of efficacy endpoints (see Sections 4.2) and PROs (see Section 7.1) will be based', 'on the mITT population. Supportive analyses will also be done using the PP population for', 'the ACR20/50/70, SDAI <3.3, and DAS28 (CRP) <3.2 endpoints.', 'All summaries will be presented by the treatment groups defined in Section 9.4, based on', 'randomized treatment.', 'All continuous efficacy and PRO endpoints will be summarized at each OLE visit in terms of', 'actual values, changes from Core Baseline values, changes from OLE Baseline values, and', 'changes from the last pre-OKZ values (see Section 9.4.1). All categorical parameters and', 'responder-type endpoints will be summarized in terms of number and percent of subjects in', 'each category by OLE visit. Core Baseline values, OLE Baseline values, and the last', 'pre-OKZ values will also be summarized for reference. Graphical summaries will also be', 'presented for mean actual values over time by treatment group for selected endpoints', '(e.g., DAS28 [CRP]).', 'Amendment 2: 06 March 2019', '133', 'Confidential']['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'Binary endpoints that are based on changes from baseline (e.g., ACR20) will be analyzed', 'based on changes from Core Baseline values, OLE Baseline values, and changes from the', 'last pre-OKZ values.', 'Missing efficacy data resulting from missed intermediate visits will be handled as described', 'in Section 9.4.8.', 'Missing data resulting from early treatment discontinuation will not be imputed, unless', 'otherwise specified. For binary efficacy endpoints, in addition to analyses based on observed', 'data, summaries will also be provided considering all subjects who discontinue the OLE', 'study treatment early as nonresponders at all post-discontinuation scheduled time points.', '9.4.8', 'Handling of Missing Data', 'Missing efficacy data resulting from missed intermediate visits will be imputed from the', 'surrounding visits. For binary efficacy endpoints, if the status at visits both before and after', 'the missed visit is classified as responder, the subject will be considered a responder at the', 'missed visit. Otherwise, the subject will be considered a nonresponder. If an assessment for', 'a given binary endpoint at the last visit is missing for a completing subject, data from the', '2 previous visits will be used with the same logic for determining the response status. For', 'the ACR20/50/70 endpoints, if only some components of the response criteria are missing', 'but the available components allow classifying the subject as a responder, the responder', 'category will be used. Otherwise, the method based on surrounding visits as described above', 'will be applied. Similarly, for all continuous endpoints, an average of values from the', 'surrounding visits will be imputed for the missing visit.', 'Missing efficacy data resulting from early treatment discontinuation will not be imputed.', 'Missing safety data will not be imputed.', '9.4.9', 'Pharmacokinetic/Pharmacodynamic Correlations', 'No PK/PD correlations are planned for this study.', '9.4.10', 'Immunogenicity', 'Immunogenicity results, including overall ADA results (Screening, confirmatory, and titers,', 'as appropriate), neutralizing ADA results, and the time course of antibodies (defined as the', 'time to first observation of a positive ADA response) will be listed. The number and', 'percentage of subjects testing positive for ADAs or neutralizing antibodies will be', 'summarized by dose treatment group over time. If applicable, the time course of antibodies', 'may be summarized by treatment group using appropriate descriptive statistics.', 'Amendment 2: 06 March 2019', '134', 'Confidential']\n\n###\n\n", "completion": "END"}